Article
Multidisciplinary Sciences
Masaichi Kato, Ken Sugimoto, Kentaro Ikeya, Ryosuke Takano, Ai Matsuura, Takahiro Miyazu, Natsuki Ishida, Satoshi Tamura, Shinya Tani, Mihoko Yamade, Yasushi Hamaya, Moriya Iwaizumi, Satoshi Osawa, Takahisa Furuta, Hiroyuki Hanai
Summary: This study investigated the correlation between ADA monitoring and real-world IBD clinical outcomes, finding that ADA continuity was associated with AAA positivity and serum ADA levels. Significant differences were observed between endoscopic remission and non-remission groups based on serum ADA levels.
Article
Medicine, General & Internal
Lea Bolcato, Anne Thiebaut-Bertrand, Francoise Stanke-Labesque, Elodie Gautier-Veyret
Summary: Isavuconazole (ISA), a triazole antifungal agent, is used for the treatment of invasive aspergillosis and mucormycosis. Therapeutic drug monitoring (TDM) is crucial for treatment efficacy, and this study investigated the inter- and intra-individual variability of ISA trough concentrations (Cmin) and identified the determinants involved, including dose, aspartate aminotransferase, and protein levels.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, General & Internal
Laida Elberdin, Rosa M. Fernandez-Torres, Maria Mateos, Maria Outeda, Eva Blanco, Maria I. Gomez-Besteiro, Isabel Martin-Herranz, Eduardo Fonseca
Summary: This study found a positive correlation between ustekinumab concentration and clinical response in psoriatic patients, suggesting ustekinumab concentration could be used to predict treatment efficacy. The presence of anti-ustekinumab antibodies may serve as a potential cause for treatment failure.
FRONTIERS IN MEDICINE
(2022)
Article
Gastroenterology & Hepatology
Hisashi Hirayama, Yasuhiro Morita, Takayuki Imai, Kenichiro Takahashi, Atsushi Yoshida, Shigeki Bamba, Osamu Inatomi, Akira Andoh
Summary: This study aimed to identify the optimal ustekinumab (UST) trough levels predicting clinical, laboratory, and endoscopic remission in Crohn's disease patients. The results showed that higher UST trough levels were required to achieve endoscopic remission compared to normalization of C-reactive protein and serum albumin levels.
BMC GASTROENTEROLOGY
(2022)
Review
Medicine, General & Internal
Sophie Restellini, Waqqas Afif
Summary: The aim of TDM is to optimize the treatment of IBD patients with biologic agents, particularly newer agents like ustekinumab and vedolizumab. The use of TDM with these newer agents is still in its infancy, and the clinical utility of TDM with non-anti-TNF mechanisms of action remains unclear. This review summarizes the latest pharmacokinetic data on newer biologics and oral small molecules, emphasizing the threshold concentrations associated with improved outcomes in IBD patients.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Biochemical Research Methods
Nynke Wijbenga, Marjolein M. Muller, Rogier A. S. Hoek, Bas J. Mathot, Leonard Seghers, Joachim G. J. Aerts, Brenda C. M. de Winter, Daniel Bos, Olivier C. Manintveld, Merel E. Hellemons
Summary: Close monitoring of immunosuppressant levels is essential for preventing complications after lung transplantation. The use of electronic nose technology as a non-invasive alternative for therapeutic drug monitoring shows weak correlation and inaccurate diagnostic and categorization capacity.
JOURNAL OF BREATH RESEARCH
(2023)
Article
Pharmacology & Pharmacy
Marleen Bouhuys, Paola Mian, Patrick F. van Rheenen
Summary: Ustekinumab shows efficacy in pediatric Crohn's disease, but there is limited research on dosing, target trough levels, and therapeutic drug monitoring. Gradually escalating the dose may improve the response to ustekinumab. Further studies are needed to determine the long-term efficacy and optimal trough levels in children.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Chemistry, Medicinal
Ruben A. G. van Eerden, Esther Oomen-de Hoop, Aad Noordam, Ron H. J. Mathijssen, Stijn L. W. Koolen
Summary: Therapeutic drug monitoring (TDM) is important in oncology for small molecule kinase inhibitors (SMKIs) to ensure optimal drug exposure, and extrapolating randomly taken drug concentrations to trough concentrations using elimination half-life is a feasible method for multiple SMKIs. Timing of blood withdrawals and specific extrapolation methods may vary for different SMKIs.
Article
Gastroenterology & Hepatology
Yushan Pan, Waseem Ahmed, Prerna Mahtani, Rochelle Wong, Randy Longman, Dana Jeremy Lukin, Ellen J. Scherl, Robert Battat
Summary: Data on therapeutic drug monitoring in postoperative Crohn's disease are limited. This study found that higher concentrations of tumor necrosis factor antagonists were associated with improved outcomes, while ustekinumab concentrations did not show a relationship with outcomes.
INFLAMMATORY BOWEL DISEASES
(2022)
Article
Medicine, General & Internal
Nicolae-Catalin Mechie, Merle Burmester, Eirini Mavropoulou, Yiannis Pilavakis, Steffen Kunsch, Volker Ellenrieder, Ahmad Amanzada
Summary: Ustekinumab (UST) is effective in improving clinical symptoms and achieving corticosteroid-free remission in patients with Crohn disease (CD). However, UST trough levels may not be predictive of treatment outcomes or disease progression. Further research is needed to determine the association between UST trough levels and treatment efficacy in CD patients.
Article
Rheumatology
Ryan M. Hum, Pauline Ho, Nisha Nair, Meghna Jani, Ann W. Morgan, John D. Isaacs, Anthony G. Wilson, Kimme L. Hyrich, Darren Plant, Anne Barton
Summary: This study suggests that higher levels of TNF-a inhibitor serum drug levels (SDLs) are associated with good treatment response in fully adherent patients. Interventions to improve SDLs, such as encouraging adherence, may improve treatment response. The identified SDL cut-offs for adalimumab and certolizumab may be useful in clinical practice.
Article
Gastroenterology & Hepatology
Claire Liefferinckx, Antoine Hubert, Debby Thomas, Jeremie Bottieau, Charlotte Minsart, Anneline Cremer, Leila Amininejad, Francois Vallee, Jean-Francois Toubeau, Denis Franchimont
Summary: This study aims to evaluate the impact of Ustekinumab (UST) pharmacokinetics (PK) in Crohn's disease (CD) patients and find predictive markers of UST response. The results show a relationship between early UST drug concentrations and clinical and endoscopic outcomes.
DIGESTIVE AND LIVER DISEASE
(2023)
Article
Gastroenterology & Hepatology
Waqqas Afif, Bernie Sattin, Dorota Dajnowiec, Reena Khanna, Cynthia H. Seow, Martin Williamson, Kinda Karra, Yanli Wang, Long-long Gao, Brian Bressler
Summary: In consecutive CD patients treated with UST, the addition of TDM into routine clinical practice did not significantly impact clinical decisions and there was no association between short-term clinical outcomes and serum [UST]. Further studies are warranted before clinicians routinely implement UST TDM into clinical practice.
DIGESTIVE DISEASES AND SCIENCES
(2022)
Article
Pharmacology & Pharmacy
Sonja E. Zapke, Stefan Willmann, Scott-Oliver Grebe, Kristin Menke, Petra A. Thurmann, Sven Schmiedl
Summary: The study compared the performance of a PBPK model for cyclosporine and found that 86% of predicted cyclosporine trough levels deviated less than twofold from observed values. The model did not fully cover the high intra-individual variability of observed cyclosporine levels. Considering clinical and additional patient-related factors may improve the model's performance.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Infectious Diseases
Qingze Gu, Nicola Jones, Philip Drennan, Tim Ea Peto, A. Sarah Walker, David W. Eyre
Summary: This study evaluated the effectiveness of an antimicrobial guideline for vancomycin prescribing using electronic prescribing aid and web/phone-based app. The compliance with the guideline for dosing was generally good, but the proportion of drug levels reaching the target range was suboptimal. The study also suggests that routinely collected electronic healthcare record data can be used to refine antimicrobial dosing recommendations.
JOURNAL OF INFECTION
(2022)
